Loading clinical trials...

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

NCT05675059•H. Lee Moffitt Cancer Center and Research Institute

View on ClinicalTrials.gov

Summary

The purpose of the study is to assess the feasibility and participant satisfaction with the Support through Remote Observation and Nutrition Guidance (STRONG) program. The program provides enhanced dietician access and nutrition support for participants living with pancreatic cancer who are receiving chemotherapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years of age or older
•Diagnosed metastatic or newly recurrent pancreatic cancer or locally advanced pancreatic cancer
•Receiving chemotherapy under the guidance of Moffitt
•Able to speak and read English
•Able to provide informed consent

Exclusion Criteria

•Documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., psychosis, active substance abuse).
•Undergoing concurrent treatment for a second primary GI cancer
•ECOG status of 2 or greater
•Use of parenteral or enteral nutrition
•Presence of malignant ascites

Locations (1)

Moffitt Cancer Center

Tampa, Florida, United States

Key Dates

Start Date

December 21, 2022

Primary Completion Date

November 22, 2025

Completion Date

June 1, 2026

Last Updated

February 9, 2026

Enrollment

ACTUAL participants

Conditions

Pancreatic Cancer

Interventions

Consultations with Moffitt Dietician

BEHAVIORAL

Daily Food Intake Diary with Fitbit Smartphone application

BEHAVIORAL

Questionnaires

BEHAVIORAL

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients